JAKARTA, AYOBANDUNG.COM – Researcher at the Indonesian Institute of Sciences Biotechnology Research Center (LIPI) Wien Kusharyoto said, before Indonesia massacred usage the Covid-19 vaccine, it is better if the vaccine efficacy rate reaches 70%.
“Actually it is better if it is above 70% but from the FDA (United States Food and Drug Administration) they say that if the effectiveness is 50% then it can continue to the next stage,” Wien said as quoted by Antara, Monday (5/10 / 2020).
Vaccines are said to be effective if they can stimulate the body’s response to produce antibodies to fight germs such as viruses or bacteria.
According to Wien, if the level of efficacy or efficacy the Covid-19 vaccine developed by Indonesia is above 70%, it can achieve population immunity or herd immunity.
“For example, 70% means that if the entire population is vaccinated in Indonesia, 70 percent of them just think that they are protected, protected from their disease is enough to obtain herd immunity,” he said.
If the vaccine has been injected and the immune system is built, it is hoped that activities in the community can run more safely and productively.
Wien said the Covid-19 vaccine created must be effective, safe and do not cause side effects.
“Seventy percent means that it is effective, safe and does not cause side effects. Even if it causes side effects, you want it to be tolerated. For example, some vaccines cause dizziness, a little nausea,” he said.
Meanwhile, Minister of Research and Technology (Menristek) Bambang PS Brodjonegoro wanted it Red and White vaccine developed must be as effective as possible to build body antibodies against the SARS-CoV-2 virus that causes Covid-19.
“The target is as effective as possible and can generate antibodies in vaccine recipients against exposure to the Covid-19 virus. Therefore, we are using virus isolates transmitting in Indonesia,” said Minister of Research and Technology Bambang in Jakarta, Monday.
Seeds Red and White vaccine it is being developed by the Eijkman Institute for Molecular Biology using the SARS-CoV-2 virus isolate that causes Covid-19 circulating in Indonesia. The vaccine was developed on a recombinant protein subunit platform.
– .
